These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 2558829

  • 21. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S, Cianciolo G, Donati G, Colì L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F.
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [Abstract] [Full Text] [Related]

  • 22. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y.
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
    Kozlova TV, Shilo VIu, Denisov AIu.
    Klin Med (Mosk); 2005 May; 83(9):45-9. PubMed ID: 16279040
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
    Ljungberg B, Blombäck M, Johnsson H, Lins LE.
    Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
    [Abstract] [Full Text] [Related]

  • 29. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
    Nimmerfall K, Mischke R.
    Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
    [Abstract] [Full Text] [Related]

  • 30. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK, Berry LR, Monagle PT, Andrew M.
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [Abstract] [Full Text] [Related]

  • 31. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P, Reynaud J, Tardy-Ponce B, Laporte-Simitsidis S, Scully M, Goodwyn C, Queneau P, Decousus H.
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.
    Ljungberg B, Jacobson SH, Lins LE, Pejler G.
    Clin Nephrol; 1992 Aug; 38(2):97-100. PubMed ID: 1325310
    [Abstract] [Full Text] [Related]

  • 35. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P, Kiehl R, von Blohn G, Köhler M, Meierhenrich U, Wenzel E.
    Thromb Haemost; 1986 Oct 21; 56(2):225-8. PubMed ID: 3810557
    [Abstract] [Full Text] [Related]

  • 36. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G, Aberg W, Johansson M, Törnebohm E, Granqvist S, Lockner D.
    Thromb Haemost; 1990 Dec 28; 64(4):506-10. PubMed ID: 1964751
    [Abstract] [Full Text] [Related]

  • 37. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV.
    Haematologica; 2003 Oct 28; 88(10):1157-62. PubMed ID: 14555312
    [Abstract] [Full Text] [Related]

  • 38. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E, Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators.
    Circulation; 2005 Dec 20; 112(25):3846-54. PubMed ID: 16291601
    [Abstract] [Full Text] [Related]

  • 39. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE.
    Thromb Res; 2008 Dec 20; 122(2):211-20. PubMed ID: 18262226
    [Abstract] [Full Text] [Related]

  • 40. Objective assessment of heparin requirements for hemodialysis in humans.
    Ireland H, Lane DA, Curtis JR.
    J Lab Clin Med; 1984 Apr 20; 103(4):643-52. PubMed ID: 6230409
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.